Reading a Protocol: The Sections That Matter

Part of Clinical Research Coordinator (CRC) Training: The Protocol and Study Design.

About 6 minutes. Free, in your language, no account needed.

Why this matters

The protocol is the rulebook for your study. Nearly every question you will be asked has its answer inside it: whether this person is eligible, whether this visit is on time, whether this counts as a deviation, whether this test was supposed to happen today.

Coordinators who rely on the training slides instead of the protocol get things wrong slowly and confidently. Read the document.

What a protocol is

A protocol is the sponsor's written plan for the trial. It states why the study is being done, who may take part, what will be done to them, what will be measured, and how the results will be analyzed. Regulators, ethics committees, investigators, monitors and coordinators all work from the same document.

It is approved as a whole, in versions. When it changes, the change is issued as an amendment, and Module 5 and Module 10 both come back to version control.

The sections, and what each one is for

Synopsis or summary. A short overview at the front: title, phase, indication, design, headline eligibility, number of participants, main objectives, and the visit outline. Use it to orient yourself and to brief new staff. Never use it to answer a specific question.

Background and rationale. Why the study is worth doing and what is already known. You will draw on this when a participant asks why the trial exists.

Objectives and endpoints. The objectives are the questions. The endpoints are the specific measurements that answer them. There will be a primary endpoint and usually several secondary ones.

Learn the primary endpoint by heart. It tells you which data point in the whole study matters most, which visit must never be missed, and which deviation will be treated most seriously.

Study design. Interventional or observational; randomized or not; the randomization ratio, such as 1:1 or 2:1; the level of blinding; the comparator; the number of arms; and a diagram of how a participant moves through the study.

Inclusion and exclusion criteria. The rules for who may take part. Inclusion criteria must all be met. Exclusion criteria must all be absent. Module 6, Lesson 2 covers how to apply them.

Study procedures and the schedule of assessments. Usually a large table, often abbreviated as SOA, showing every visit and every procedure at it, with the allowed visit window, such as day 28 plus or minus 3 days. This table will be open on your desk more than any other page.

Treatment plan and investigational product administration. Dose, route, frequency, any titration or dose-adjustment rules, what to do about missed doses, and any required pre-medication.

Safety assessments and adverse event reporting. Which safety tests are done and when, how adverse events are defined and graded, how seriousness and causality are assessed, and the reporting timelines for this study. Module 9 is built on this section.

Concomitant medications and prohibited therapies. What a participant may keep taking, what they must stop, and what triggers a decision if a prohibited medicine becomes necessary.

Withdrawal and discontinuation. When a participant must be discontinued, when they may withdraw, and what follow-up is still required afterwards. Withdrawal from treatment and withdrawal from follow-up are not the same thing, and confusing them loses data that could have been kept.

Statistical considerations. Sample size, the analysis populations, and how missing data will be handled. Lesson 3 of this module explains why this affects you.

Data handling and deviations. How data are recorded, and how the study defines and reports protocol deviations.

Ethics and regulatory. Consent requirements, confidentiality, and the approvals needed.

How to actually read it

You will not memorize a 120-page document. Do this instead.

  1. Read it once, all the way through, before the site initiation visit. Not the slides. The document.
  2. Build your own one-page summary: primary endpoint, visit windows, the three eligibility criteria most likely to be misread, prohibited medicines, and the safety reporting deadline.
  3. Tab or bookmark five sections: eligibility, the schedule of assessments, investigational product dosing, safety reporting, and concomitant medications. These are the five you will open weekly.
  4. Keep the current version accessible in the clinic, not filed in a cupboard, and be certain it is the current version.
  5. Write down your questions and ask them. If the protocol is ambiguous, do not resolve it yourself. Ask the monitor or the sponsor's medical monitor and file the written answer so that the next person finds the same interpretation.

In practice

VT-201 states that eligible participants must have a seated systolic blood pressure of 140 mmHg or above at screening, measured after five minutes of rest, as the average of three readings taken two minutes apart.

Nadia screens a man whose first reading is 152. He is clearly eligible on that number, and the clinic is busy.

She takes all three readings anyway, spaced as required, after the full rest period. The average is

  1. He is not eligible.

She records the readings, the times, and the screen failure with its reason. Enrolling him would have been a deviation on an eligibility criterion, and eligibility deviations are among the most serious kind, because they undermine both the participant's safety case and the analysis.

Two months later a monitor reviews the screening log and asks about this participant. The answer is already in the record.

The protocol did not say "confirm high blood pressure". It said exactly how to measure it. That detail is the requirement.

Key takeaways